Yeni tanı konulan ankilozan spondilitli hastalarda epikardiyal yağ dokusu kalınlığı hastalık ciddiyeti ile ilişkili

Epicardial adipose tissue thickness is associated with disease severity in patients with newly-diagnosed ankylosing spondylitis

Zafer Büyükterzi1, Mehmet Sertaç Alpaydın1, Halil Ekrem Akkurt2, Halim Yılmaz2

1Konya Eğitim Araştırma Hastanesi, Kardiyoloji Kliniği, Konya, Türkiye
2Konya Eğitim Araştırma Hastanesi, Fizik Tedavi Ve Rehabilitasyon Kliniği, Konya, Türkiye

ÖZ

GİRİŞ ve AMAÇ: Inflamatuar hastalıklarda kardiyovasküler hastalıkların eşlik ettiği daha önceki çalışmalarında tanımlanmıştır. Geleneksel risk faktörlerinin yanı sıra epikardiyal yağ dokusu koroner ateroskleroz gelişimi ve ilerlememesine katkıda bulunur. Bu çalışmada yeni tanı konulan ankilozan spondilitli (AS) hastalarda transtorasik ekokardiyografi ile ölçülen epikardiyal yağ doksu kalınlığı ile hastalık ciddiğin arasındaki ilişkisini araştırmaya amaçladık.

YÖNTEM ve GEREÇLER: Bu retrospektif çalışmada yeni tanı konulan ankilozan spondilitli hastaların transtorasik ekokardiyografi raporları tarandı. Ayrıca katılım kriterlerini sağlayan yaş ve cinsiyet eşlenik bireyler control grubu olarak çalışmaya dahil edildi.

BULGULAR: 100 birey [40.00 (34.25-48.00) yıl, 65% erkek] çalışmaya dahil edildi. Epikardiyal yağ dokusu kalınlığı AS’li hastalarda control grubuna göre artmıştı (p<0.001). Spearman’s korelasyon analizinde epikardiyal yağ dokusu kalınlığı ile AS hastalığı aktivite skoru koreleydi (r=0.652, p<0.001). Ayrıca lineer regresyon analizinde epikardiyal yağ dokusu kalınlığı, AS hastalığı aktivite skoru ile bağımsız olarak ilişkilendi (p=0.001).

TARTIŞMA ve SONUÇ: AS hastalığı aktivite skoru, yeni tanı konmuş AS’li hastalarda epikardiyal yağ dokusu kalınlığı ile bağımsız olarak ilişkilidir. İlk tanida AS hastalığı aktivite skoru hastaların kardiyovasküler risk ve primer koruma stratejisi için yol gösterici olabilir.

Anahtar Kelimeler: ankilozan spondilit, epikardiyal yağ dokusu, kardiyovasküler hastalık

ABSTRACT

INTRODUCTION: Cardiovascular (CV) disease is a well-described co-morbidity in patients with inflammatory arthritis. Epicardial adipose tissue (EAT) contributes to the development and progression of coronary atherosclerosis independent of traditional CV risk factors. In this study, we aimed to investigate whether EAT thickness determined by transthoracic echocardiography (TTE) in newly-diagnosed ankylosing spondylitis (AS) patients is associated with AS severity.

METHODS: In this retrospective study, TTE reports of newly-diagnosed AS patients were reviewed. Age- and gender-matched control subjects who fulfilled the inclusion criteria were also included in the study.

RESULTS: 100 subjects [40.00 (34.25-48.00) years, 65% male] were included in the study. EAT thickness was significantly increased in AS patients when compared to the controls (p<0.001). In Spearman’s correlation analysis, EAT thickness in AS patients was found to be positively correlated with the Ankylosing Spondylitis Disease Activity Score (ASDAS) (r=0.652, p<0.001). In the linear regression analysis, EAT thickness was found to be independently associated with ASDAS (p=0.001).

DISCUSSION AND CONCLUSION: Our results indicates that ASDAS is independently associated with EAT thickness in newly-diagnosed AS patients. ASDAS at the first diagnosis may guide the patient’s CV risk and primary prevention strategies.

Keywords: ankylosing spondylitis, epicardial adipose tissue, cardiovascular disease
INTRODUCTION

Cardiovascular (CV) disease is a well-described co-morbidity in patients with inflammatory arthritis. Although the relationship between rheumatoid arthritis (RA) and CV morbidity and mortality is primarily investigated in previous studies(1-4), an association also exists between the wide spectrum of CV disease (CVD) and axial spondylo arthritis including ankylosing spondylitis (AS), psoriatic arthritis, and gouty arthritis(5, 6).

Epicardial adipose tissue (EAT) is the visceral adipose tissue of the heart, that is known to cover 80% of the heart’s surface(7). Due to its numerous metabolic and endocrine functions, increased thickness of EAT has been suggested to contribute to risk of developing CVD and metabolic syndrome in various studies(8-10). EAT thickness has also been associated with the presence and severity of coronary artery disease (CAD)(11-15). These studies have demonstrated that EAT thickness contribute to the development and progression of coronary atherosclerosis independent of traditional CV risk factors(11-15).

In this study, we aimed to investigate whether EAT thickness determined by transthoracic echocardiography in patients with newly-diagnosed AS is associated with AS severity, reflected with Ankylosing Spondylitis Disease Activity Score (ASDAS), which may guide the primary prevention strategies from CVD in AS patients.

MATERIALS AND METHODS

Study population

Patients who were newly-diagnosed with AS in Department of Physical Medicine and Rehabilitation were included in the study. Patients with a prior history of hypertension, hyperlipidemia, diabetes mellitus, smoking; concomitant infectious and inflammatory diseases; known or suspected cardiovascular diseases and/ or malignancy were excluded. Age and gender-matched control subjects who fulfilled the inclusion criteria were recruited from outpatient clinics of Department of Cardiology. Detailed medical history, laboratory and physical examination findings and transthoracic echocardiography (TTE) reports were reviewed for all subjects. In the patient group, diagnosis of AS was made using the modified New York criteria(16). ASDAS was used to determine disease activity in AS patients(17). A previous study(18) has developed and validated an Assessment of SpondyloArthritis international Society (ASAS)-endorsed ASDAS consisting of total back pain, duration of morning stiffness, the BASDAI question on peripheral joints, patient global assessment of disease activity and CRP, whereas ESR for the acute phase reactant could be used in cases when CRP is not available.

Measurement of EAT thickness

All patients underwent a comprehensive transthoracic echocardiographic (TTE) examination during sinus rhythm. PhilipsEpiq 7® Ultrasound Machine with a 3.6 MHz probe was used. Echocardiographic measurements were acquired from three consecutive beats. Epicardial fat was identified as the echo-free space between the outer wall of the myocardium and the visceral layer of pericardium. EAT thickness was measured perpendicularly on the free wall of the right ventricle at end-systole in three cardiac cycles on Standard parasternal views. Maximum EAT thickness was measured at the point on the free wall of the right ventricle along the midline of the ultrasound beam, perpendicular to the aortic annulus, used as anatomical landmark for this view. The average value of three cardiac cycles from each echocardiographic view was taken into account.

Statistical analysis

Normally distributed parameters were presented as mean± standard deviation and skewed parameters were expressed as median (interquartile range defined as 25-75th percentiles). Descriptive data were presented as frequencies (number and percentage) and compared using chi-square test. Univariate analyses were performed on continuous variables with the use of the independent student’s t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed data. Spearman correlation analysis was used to demonstrate the correlation between EAT thickness and baseline characteristics. Linear regression analysis was used for identifying factors that were independently correlated with EAT thickness. Statistical analyses were performed using SPSS statistical software (version 21.0; SPSS Inc., Chicago, Illinois, USA). A two-tailed p < 0.05 was considered statistically significant.
RESULTS

100 subjects [40.00 (34.25- 48.00) years, 65% male] were included in the study. Baseline characteristics of the study population are shown in Table 1. Age and gender did not differ among patient and control groups. EAT thickness was significantly increased in AS patients when compared to the controls. Furthermore, serum C- reactive protein levels (CRP) and erythrocyte sedimentation rate (ESR) were significantly increased in AS patients when compared to the controls (Table 1).

Table 1. Baseline characteristics of the study population (n= 100).

| Parameters                                      | Study population (n= 100) | Control group (n= 50) | Ankylosing spondylitis patients (n= 50) | p value |
|------------------------------------------------|--------------------------|-----------------------|------------------------------------------|---------|
| Age (years)                                     | 40.00 (34.25- 48.00)     | 40.00 (34.00- 46.00)  | 39.00 (35.00- 45.00)                     | 0.786   |
| Gender: male n (%)                              | 65 (65.00)               | 32 (64.00)            | 33 (66.00)                               | 0.904   |
| Body mass index (kg/m²)                         | 25.12± 4.17              | 25.66± 4.41           | 24.22± 3.11                             | 0.119   |
| Left ventricular enddiastolic diameter (mm)    | 45.53± 3.73              | 45.46± 3.80           | 45.59± 3.71                             | 0.883   |
| Left ventricular ejection fraction (%)          | 62.65± 4.54              | 62.00± 5.01           | 62.68± 4.10                             | 0.947   |
| Left atrial diameter (mm)                       | 35.66± 3.81              | 35.90± 2.97           | 36.90± 3.81                             | 0.193   |
| Epicardial adipose tissue thickness (mm)        | 4.00 (3.25- 5.10)        | 3.50 (3.10- 4.00)     | 4.75 (3.80- 6.05)                       | <0.001* |
| C- reactive protein (mg/dL)                     | 10.30 (3.33- 32.55)      | 9.00 (6.00- 13.00)    | 10.30 (3.33- 32.55)                     | 0.025*  |
| Erythrocyte sedimentation rate (mm/ hr)         | 37.00 (16.00- 50.50)     | 27.00 (21.00- 32.00)  | 37.00 (16.00- 50.00)                     | 0.009*  |
| White blood cell count (x10³/µL)                | 7.20 (6.30- 9.05)        | 6.90 (6.00- 8.80)     | 7.30 (6.40- 9.20)                       | 0.206   |
| High density lipoprotein-cholesterol (mg/dL)    | 48.00 (40.75- 55.25)     | 50.50 (42.25- 57.75)  | 46.00 (40.00- 54.00)                     | 0.643   |
| Low density lipoprotein-cholesterol (mg/dL)     | 130.50 (107.25- 152.00)  | 121.50 (98.75- 156.50)| 138.50 (110.00- 150.00)                 | 0.356   |
| Triglyceride (mg/dL)                            | 116.50 (87.00- 170.75)   | 111.00 (86.50- 172.25)| 132.50 (87.00- 170.50)                  | 0.552   |
| Total cholesterol (mg/dL)                       | 200.50 (177.75- 225.50)  | 194.00 (160.25- 230.75)| 208.00 (184.00- 224.00)                 | 0.335   |
| Fasting blood glucose (mg/dL)                   | 96.50 (86.00- 107.25)    | 96.50 (89.50- 105.75)  | 97.50 (85.75- 108.50)                    | 0.126   |

* denotes statistical significance.

Of 50 patients, 24 had high (2.1- 3.5) or very high (>3.5) disease activity, where 26 of them had inactive disease (<1.3) or low (1.3- 2.1) disease activity according to ASDAS scores. EAT thickness was significantly higher in patients with high or very high disease activity, when compared to patients with inactive disease or low disease activity [0.54 (0.47- 0.72) vs. 0.40 (0.31- 0.46) cm, p<0.001]. In Spearman’s correlation analysis, EAT thickness in AS patients was found to be positively correlated with ASDAS (r=0.652, p<0.001) (Table 2). In the linear regression analysis, EAT thickness was found to be independently associated with ASDAS and thereby with the disease activity in the newly-diagnosed AS patients (Table 3).
Table 2. Correlation of epicardial adipose tissue thickness and baseline characteristics in patients with ankylosing spondylitis (n= 50)

|                | Spearman's rho | Epicardial adipose tissue thickness |
|----------------|----------------|------------------------------------|
|                |                | Correlation coefficient | P value |
| **Age (years)**|                | .167 | .251 |
| **Body mass index (kg/m²)** |                | .084 | .560 |
| **Left ventricular ejection fraction (%)** |                | -.039 | .808 |
| **Left ventricular end- diastolic diameter (mm)** |                | .136 | .397 |
| **Left atrial diameter (mm)** |                | .093 | .563 |
| **ASDAS**      |                | .652 | <0.001* |
| **C- reactive protein (mg/dL)** |                | .228 | .151 |
| **Erythrocyte sedimentation rate (mm/ hr)** |                | .117 | .465 |
| **White blood cell count (x10³/µL)** |                | .023 | .879 |
| **High- density lipoprotein- cholesterol (mg/dL)** |                | .023 | .884 |
| **Low- density lipoprotein- cholesterol (mg/dL)** |                | .152 | .338 |
| **Triglyceride (mg/dL)** |                | .125 | .429 |
| **Total cholesterol (mg/dL)** |                | .204 | .195 |
| **Fasting blood glucose (mg/dL)** |                | .082 | .646 |

ASDAS ankylosing spondylitis disease activity score.

Table 3. Linear regression analysis to determine independent associates of epicardial adipose tissue thickness in patients with ankylosing spondylitis (n= 50).

| Variable                          | Univariate model | Multivariate model |
|-----------------------------------|------------------|--------------------|
|                                   | Unstandardized   | 95% Confidence     | Unstandardized   | 95% Confidence     |
|                                   | Coefficients     | Interval for B     | Coefficients     | Interval for B     |
|                                   | Sig.             | Lowerr Bound       | Upperr Bound     | Sig.              | Lower Bound       | Upper Bound       |
| B Std. Error                      |                  |                    | B Std. Error     |                  |                    |                    |
| ASDAS                             | 0.196            | 0.034              | <0.001*          | 0.127            | 0.265              | 0.162            | 0.044              | 0.001*             | 0.072              | 0.252              |
| C- reactive protein (mg/ dl)      | 0.001            | 0.001              | 0.142            | 0.000            | 0.002              | 0.000            | 0.001              | 0.821              | -0.002              | 0.003              |
| Total cholesterol (mg/ dl)        | 0.001            | 0.000              | 0.181            | 0.000            | 0.002              | 0.000            | 0.001              | 0.509              | -0.001              | 0.002              |

ASDAS ankylosing spondylitis disease activity score.
* denotes statistical significance.
DISCUSSION

Findings of our study are unique for demonstrating the significant association between ASDAS and EAT thickness, as a surrogate marker of CVD risk, in newly-diagnosed AS patients.

Although an association between AS and CVD other than coronary artery disease, such as hypertension(19) and left ventricular diastolic dysfunction(20), has been documented, due to the young age of AS patients at the time of diagnosis, evaluation of ischemic CVD risk in AS has been relatively hard and studies that have been performed have led to inconsistent results. A meta analysis published in 2011 has shown that AS patients did not have increased risk of cardiovascular events when compared to healthy controls (21). However, a population-based study that was not included to the meta-analysis has shown an increased prevalence of CVA, ischemic heart disease, and peripheral vascular disease in 8,616 AS subjects(22). Another population-based study has also reported an increased standardized morbidity rate ratio of ischemic heart disease (IHD) in 935 AS subjects(23). Despite a negative association for CV and cerebrovascular events in 1,686 AS subjects and 1,206.621 controls in Wales(24), an increased hazard ratio (HR) for incident IHD in AS subjects compared to non-AS controls have been reported in a Taiwanese population(25).

There are currently no studies in the literature evaluating the associates of CVD risk in newly-diagnosed AS patients. A previous study has shown that EAT thickness was higher in AS patients when compared to the controls and there was a significant correlation between carotid intima-media thickness and EAT thickness in AS patients(26). However both were also significantly correlated with duration of disease(26). Our study demonstrates that EAT thickness is significantly higher in newly-diagnosed AS patients when compared to controls and that EAT thickness is significantly correlated to disease severity. Considering the previously documented link between EAT thickness and CVD, EAT thickness in newly-diagnosed AS patients may suggest the association between AS and CVD. ASDAS at first diagnosis may be an indirect determinant of future CVD risk in these patients.

Echocardiography, computed tomography (CT) and magnetic resonance imaging (MRI) may be used to evaluate EAT thickness. Echocardiography allows quick and adequate assessment of EAT in most clinical situations. It provides reliable data, since echocardiographic measurement of EAT thickness have been shown to be correlated with MRI measurements (r = 0.91, p = 0.001)(9). Echocardiography is performed with low cost, is not time-consuming, and does not require any special software for analysis of data. Points under debate for the use of echocardiography include the location of measurement and determination of most suitable time in the cardiac cycle (since some recommends the measurement during systole to prevent possible deformation by compression during diastole(27) and others in diastole, to coincide with other imaging modalities(28).

Role of CT and MRI is increasing due to high spatial resolution and the possibility of volumetric assessment. MRI is considered the gold standard for the assessment of total body fat, and also the detection and quantification of EAT(9). The interobserver reproducibility of EAT volume measurement has been reported to be superior to the EAT thickness measurement; however, it is technically more difficult. The measurement of maximum EAT thickness is more feasible, without significant accuracy decrease (29, 30). For EAT measurements by CT, there is no need to use contrast (unless obtained from CT angiography); however, radiation exposure occurs at a predetermined phase of the cardiac cycle (65-85% of RR interval). EAT thickness, volume and total area can be accurately measured by CT. The difficulty in standardizing measurement locations limits the determination of EAT thickness reference values by CT. Similar to echocardiography, EAT thickness assessment by CT is susceptible to interobserver variability, however may be minimized by EAT volume measurement (31, 32).
There are several limitations of this study. First, this is a retrospective study, and reveals only an association. Second, our sample size is relatively small. Third, subclinical atherosclerosis markers, other than EAT have not been assessed.

**CONCLUSION**

Our results indicates that ASDAS is independently associated with EAT thickness in newly-diagnosed AS patients. ASDAS at the first diagnosis may guide the patient’s CV risk in newly-diagnosed AS patients without major CVD risk factors.

**ACKNOWLEDGEMENTS**

None.

**DECLARATION OF CONFLICT OF INTEREST**

All authors declare no conflict of interest.

**REFERENCES**

1. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis. 1999;58(1):11-4.

2. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis and rheumatism. 2005;52(2):402-11.

3. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis and rheumatism. 2005;52(3):722-32.

4. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. The American journal of medicine. 2008;121(10 Suppl 1):S9-14.

5. Gensler LS. Axial spondyloarthritis: the heart of the matter. Clin Rheumatol. 2015;34(6):995-8.

6. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. European heart journal. 2015;36(8):482-9c.

7. Rabkin SW. Epicardial fat: properties, function and relationship to obesity. Obes Rev. 2007;8(3):253-61.

8. Pierdomenico SD, Pierdomenico AM, Cucurullo F, Iacobellis G. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. The American journal of cardiology. 2013;111(1):73-8.

9. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappatarerro A, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab. 2003;88(11):5163-8.

10. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. The Journal of clinical endocrinology and metabolism. 2005;90(11):6300-2.

11. Mahabadi AA, Lehmann N, Kalsch H, Robens T, Bauer M, Dykun I, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging. 2014;7(9):909-16.

12. Mahabadi AA, Berg MH, Lehmann N, Kalsch H, Bauer M, Kara K, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. Journal of the American College of Cardiology. 2013;61(13):1388-95.

13. Sade LE, Eroglu S, Bozbas H, Ozbicier S, Hayran M, Haberal A, et al. Relation between epicardial fat thickness and coronary flow reserve in women with chest pain and angiographically normal coronary arteries. Atherosclerosis. 2009;204(2):580-5.

14. Eroglu S, Sade LE, Yildirir A, Bal U, Ozbicier S, Ozgul AS, et al. Epicardial adipose tissue thickness by echocardiography is a marker for the presence and severity of coronary artery disease. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2009;19(3):211-7.

15. Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM. Epicardial fat thickness and coronary artery disease correlate independently of obesity. International journal of cardiology. 2011;146(3):452-4.

16. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and rheumatism. 1984;27(4):361-8.
17. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47-53.

18. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-8.

19. Gensler LSW, M.M; Lee, M.J.; Rahbar, M.; Brown, M.A.; Reveille, J.D.; Weisman, M.H. Cardiovascular disease is associated with worse functional outcomes in ankylosing spondylitis. [abstract]. Arthritis and rheumatism. 2013;65 (Suppl 10):2448.

20. Heslinga SC, Van Dongen CJ, Konings TC, Peters MJ, Van der Horst-Bruinsma IE, Smulders YM, et al. Diastolic left ventricular dysfunction in ankylosing spondylitis--a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(1):14-9.

21. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis care & research. 2011;63(4):557-63.

22. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis and rheumatism. 2011;63(11):3294-304.

23. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis care & research. 2011;63(4):550-6.

24. Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis--a retrospective cohort study using routine data. Semin Arthritis Rheum. 2012;42(2):140-5.

25. Huang YP, Wang YH, Pan SL. Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study. PloS one. 2013;8(5):e64155.

26. Resorlu H, Akbal A, Resorlu M, Gokmen F, Ates C, Uysal F, et al. Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clin Rheumatol. 2015;34(2):295-9.

27. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2009;22(12):1311-9; quiz 417-8.

28. Nelson AJ, Worthley MI, Psaltis PJ, Carbone A, Dundon BK, Duncan RF, et al. Validation of cardiovascular magnetic resonance assessment of pericardial adipose tissue volume. J Cardiovasc Magn Reson. 2009;11:15.

29. Fluchter S, Haghi D, Dinter D, Heberlein W, Kuhl HP, Neff W, et al. Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. Obesity (Silver Spring). 2007;15(4):870-8.

30. Schejbal V. [Epicardial fatty tissue of the right ventricle--morphology, morphometry and functional significance]. Pneumologie. 1989;43(9):490-9.

31. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, et al. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation. 2009;119(12):1586-91.

32. Gorter PM, de Vos AM, van der Graaf Y, Stella PR, Doevendans PA, Meijts MF, et al. Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. Am J Cardiol. 2008;102(4):380-5.